capecitabine + lenvatinib + tislelizumab

Capecitabine + lenvatinib + tislelizumab is an investigational combination therapy comprising three agents with distinct mechanisms of action, used primarily in oncology clinical trials. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), functioning as a cytotoxic antimetabolite that inhibits DNA synthesis in rapidly dividing cells. Lenvatinib is a small molecule multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT, thereby inhibiting tumor angiogenesis and proliferation. Tislelizumab is a humanized monoclonal antibody against programmed cell death protein 1 (PD-1) on T cells; it acts as an immune checkpoint inhibitor to enhance anti-tumor immune responses by preventing cancer-mediated immunosuppression. This triple combination has been studied as adjuvant therapy after resection in patients with biliary tract cancer and other digestive system neoplasms[7][9]. Each component has established roles in various cancers, but the specific three-drug regimen remains under clinical investigation.

Other names

Tislelizumab plus Lenvatinib plus CapecitabineTLC regimen